```
=> dis hist

     (FILE 'HOME' ENTERED AT 15:08:37 ON 23 AUG 2007)

     FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT,
     NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2,
     WPIFV, WPINDEX, WSCA, WTEXTILES, BIOSIS, EMBASE, MEDLINE' ENTERED AT
     15:09:00 ON 23 AUG 2007
L1         48280 S N-ACETYLGLUCOSAMINE
L2          2862 S L1 AND (AUTOIMMU? OR LESION OR INFALM?)
L3          5069 S L1 AND (AUTOIMMU? OR LESION OR INFLAM?)
L4         12947 S L1 AND TREAT?
L5          3967 S L3 AND TREAT?
L6           243 S L1 AND (AUTOIMM?(S)REACTION)
L7           242 S L6 AND TREAT?
L8           208 S L7 AND DOSAGE
L9            47 S L8 AND (1000(A)MG)

     FILE 'CAPLUS' ENTERED AT 15:16:54 ON 23 AUG 2007
L10           33 S XU QIWANG/AU
L11            1 S L10 AND N-ACETYLGLUCOSAMINE
L12           14 S L10 AND N-ACETYL-D-GLUCOSAMINE
L13           45 S LIU JUNKANG/AU
L14           11 S L13 AND N-ACETYL-D-GLUCOSAMINE
L15           19 S YUAN ZETAO/AU
L16           10 S L15 AND N-ACETYL-D-GLUCOSAMINE
```

```
Welcome to STN International!  Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAY 01  New CAS web site launched
 NEWS  3  MAY 08  CA/CAplus Indian patent publication number format defined
 NEWS  4  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                  fields
 NEWS  5  MAY 21  BIOSIS reloaded and enhanced with archival data
 NEWS  6  MAY 21  TOXCENTER enhanced with BIOSIS reload
 NEWS  7  MAY 21  CA/CAplus enhanced with additional kind codes for German
                  patents
 NEWS  8  MAY 22  CA/CAplus enhanced with IPC reclassification in Japanese
                  patents
 NEWS  9  JUN 27  CA/CAplus enhanced with pre-1967 CAS Registry Numbers
 NEWS 10  JUN 29  STN Viewer now available
 NEWS 11  JUN 29  STN Express, Version 8.2, now available
 NEWS 12  JUL 02  LEMBASE coverage updated
 NEWS 13  JUL 02  LMEDLINE coverage updated
 NEWS 14  JUL 02  SCISEARCH enhanced with complete author names
 NEWS 15  JUL 02  CHEMCATS accession numbers revised
 NEWS 16  JUL 02  CA/CAplus enhanced with utility model patents from China
 NEWS 17  JUL 16  CAplus enhanced with French and German abstracts
 NEWS 18  JUL 18  CA/CAplus patent coverage enhanced
 NEWS 19  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS 20  JUL 30  USGENE now available on STN
 NEWS 21  AUG 06  CAS REGISTRY enhanced with new experimental property tags
 NEWS 22  AUG 06  BEILSTEIN updated with new compounds
 NEWS 23  AUG 06  FSTA enhanced with new thesaurus edition
 NEWS 24  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                  patents
 NEWS 25  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records

 NEWS EXPRESS  29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:08:37 ON 23 AUG 2007

=> file polymer biosis embase medline
COST IN U.S. DOLLARS                          SINCE FILE .     TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'APOLLIT' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (c) 2007 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (c) 2007 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 15:09:00 ON 23 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (c) 2007 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 15:09:00 ON 23 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 15:09:00 ON 23 AUG 2007
Compendex Compilation and Indexing (C) 2007
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' ENTERED AT 15:09:00 ON 23 AUG 2007
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2007)

FILE 'PASCAL' ENTERED AT 15:09:00 ON 23 AUG 2007
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 15:09:00 ON 23 AUG 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'TEXTILETECH' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 15:09:00 ON 23 AUG 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:09:00 ON 23 AUG 2007

```
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WPINDEX' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WSCA' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 15:09:00 ON 23 AUG 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:09:00 ON 23 AUG 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:09:00 ON 23 AUG 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 15:09:00 ON 23 AUG 2007

=> s N-acetylglucosamine
L1       48280 N-ACETYLGLUCOSAMINE

=> s l1 and (autoimmu? or lesion or infalm?)
L2        2862 L1 AND (AUTOIMMU? OR LESION OR INFALM?)

=> s l1 and (autoimmu? or lesion or inflam?)
L3        5069 L1 AND (AUTOIMMU? OR LESION OR INFLAM?)

=> s l1 and treat?
  15 FILES SEARCHED...
L4       12947 L1 AND TREAT?

=> s l3 and treat?
  18 FILES SEARCHED...
L5        3967 L3 AND TREAT?

=> s l1 and (autoimm?(s)reaction)
  18 FILES SEARCHED...
L6         243 L1 AND (AUTOIMM?(S) REACTION)

=> s l6 and treat?
  19 FILES SEARCHED...
L7         242 L6 AND TREAT?

=> s l7 and dosage
L8         208 L7 AND DOSAGE

=> s l8 and (1000(a)mg)
L9          47 L8 AND (1000(A) MG)

=> dis l9 1-47 bib abs

L9   ANSWER 1 OF 47  USPATFULL on STN
AN     2007:191245  USPATFULL <<LOGINID::20070823>>
TI     Compounds for the treatment of inflammatory disorders and
       microbial diseases
IN     Siddiqui, M. Arshad, Newton, MA, UNITED STATES
       Mansoor, Umar Faruk, Farmingham, MA, UNITED STATES
       Reddy, Panduranga Adulla P., Walpole, MA, UNITED STATES
```

Madison, Vincent S., Mountain Lakes, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 2007167426 A1 20070719
AI US 2006-599784 A1 20061115 (11)
RLI Continuation-in-part of Ser. No. US 2005-291595, filed on 1 Dec 2005, PENDING Continuation-in-part of Ser. No. US 2005-142601, filed on 1 Jun 2005, PENDING
PRAI US 2004-576153P 20040602 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13096
AB This invention relates to compounds of the Formula (I): ##STR1## or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.

L9 ANSWER 2 OF 47 USPATFULL on STN
AN 2007:161628 USPATFULL <<LOGINID::20070823>>
TI Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
IN Henderson, Todd R., Jarrettsville, MD, UNITED STATES
Frondoza, Carmelita, Woodstock, MD, UNITED STATES
PA NUTRAMAX LABORATORIES, INC., Edgewood, MD, UNITED STATES (U.S. corporation)
PI US 2007141181 A1 20070621
AI US 2006-634383 A1 20061206 (11)
RLI Continuation-in-part of Ser. No. US 2004-824498, filed on 15 Apr 2004, PENDING Continuation of Ser. No. US 2002-192318, filed on 11 Jul 2002, GRANTED, Pat. No. US 6797289 Continuation of Ser. No. US 1999-274881, filed on 23 Mar 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-249335, filed on 12 Feb 1999, GRANTED, Pat. No. US 6451771
PRAI US 1998-74594P 19980213 (60)
US 1998-88205P 19980605 (60)
DT Utility
FS APPLICATION
LREP COVINGTON & BURLING, LLP, ATTN: PATENT DOCKETING, 1201 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC, 20004-2401, US
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 1850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-α, IL-1β, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothioneine, methylsulfanylmethane, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 47 USPATFULL on STN
AN 2007:155116 USPATFULL <<LOGINID::20070823>>
TI Therapeutic molecules
IN Collier, Greg, Victoria, AUSTRALIA
Walder, Ken, Victoria, AUSTRALIA
Kerr-Bayles, Lyndal, Victoria, AUSTRALIA
PA Autogen Research Pty Ltd., North Brighton, Victoria, AUSTRALIA (non-U.S. corporation)
Deakin University, Waurn Ponds, Victoria, AUSTRALIA (non-U.S. corporation)
PI US 2007135335 A1 20070614
AI US 2004-545099 A1 20040210 (10)
WO 2004-AU147 20040210
20060504 PCT 371 date
PRAI US 2003-446191P 20030210 (60)
DT Utility
FS APPLICATION
LREP SCULLY, SCOTT, MURPHY & PRESSER, P.C., 400 GARDEN CITY PLAZA, SUITE 300, GARDEN CITY, NY, 11530, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 6649
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to a ligand for a protein associated with modulating obesity, diabetes and metabolic energy levels in animals including humans. More particularly, the present invention provides a ligand of the protein, Beacon, and its homologs. The identification of a Beacon ligand permits the identification of agents which agonize or antagonize the Beacon-ligand interaction and, hence, the development of therapeutic molecules useful in modulating obesity, diabetes and/or energy imbalance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 47 USPATFULL on STN
AN 2007:148281 USPATFULL <<LOGINID::20070823>>
TI Compounds for the treatment of inflammatory disorders and microbial diseases
IN Siddiqui, M. Arshad, Newton, MA, UNITED STATES
Mansoor, Umar Faruk, Framingham, MA, UNITED STATES
Reddy, Panduranga Adulla P., Walpole, MA, UNITED STATES
Madison, Vincent S., Mountain Lakes, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 2007129378 A1 20070607
AI US 2006-605927 A1 20061129 (11)
PRAI US 2005-741264P 20051201 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compounds of the Formulae (I)-(IX): ##STR1## ##STR2## or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 47 USPATFULL on STN
AN 2007:148186 USPATFULL <<LOGINID::20070823>>
TI Pharmaceutical treatments and compositions
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
Carvalho, Luis Daniel dos Anjos de, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES
PI US 2007129282 A1 20070607
AI US 2004-877911 A1 20040624 (10)
RLI Continuation of Ser. No. US 2001-820483, filed on 29 Mar 2001, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, GRANTED, Pat. No. US 6667299 Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED
PRAI US 1998-109924P 19981124 (60)
US 1999-140028P 19990616 (60)
US 1998-109923P 19981124 (60)
US 1999-126056P 19990323 (60)
US 1998-110127P 19981127 (60)
US 1999-161453P 19991025 (60)
US 1999-142386P 19990706 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1998-112206P 19981215 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 3
ECL Exemplary Claim: 1-30
DRWN 6 Drawing Page(s)
LN.CNT 14056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 47 USPATFULL on STN
AN 2007:147595 USPATFULL <<LOGINID::20070823>>
TI Genomically modified cell neutralized to serum-free system

IN Nakano, Ryosuke, Machida-shi, JAPAN
Satoh, Mitsuo, Machida-shi, JAPAN
Iida, Shigeru, Machida-shi, JAPAN
Inoue, Miho, Machida-shi, JAPAN
Kusunoki, Machi, Machida-shi, JAPAN
Kinoshita, Satoko, Sunto-gun, JAPAN
Ohnuki, Naoko, Machida-shi, JAPAN
PI US 2007128691 A1 20070607
AI US 2004-575253 A1 20041008 (10)
WO 2004-JP15315 20041008
20060410 PCT 371 date
PRAI JP 2003-350166 20031009
DT Utility
FS APPLICATION
LREP NIXON & VANDERHYE, PC, 901 NORTH GLEBE ROAD, 11TH FLOOR, ARLINGTON, VA, 22203, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 5449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Development of a host cell capable of producing a glycoprotein composition such as an antibody composition which is useful in development of medicaments is desired. The present invention provides a cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the cell is naturalized in a serum-free medium and a process for producing a glycoprotein composition using the cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 47 USPATFULL on STN
AN 2007:68522 USPATFULL <<LOGINID::20070823>>
TI High throughput glycan microarrays
IN Blixt, Ola, La Jolla, CA, UNITED STATES
Head, Steve, San Diego, CA, UNITED STATES
PI US 2007059769 A1 20070315
AI US 2006-516014 A1 20060905 (11)
RLI Continuation of Ser. No. WO 2005-US7370, filed on 7 Mar 2005, PENDING
PRAI US 2004-550667P 20040305 (60)
US 2004-558598P 20040331 (60)
US 2004-629833P 20041119 (60)
DT Utility
FS APPLICATION
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402, US
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 15073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides arrays of glycans for detecting entities that bind to glycans. In some embodiments, the arrays can be used to detect disease, blood types, antibodies, bacterial or viral infection, cancer, and the like. The invention also provides methods and kits for such detection. In another embodiment, the invention provides methods of preventing or treating disease in a mammal by administering to the mammal a composition that includes at least glycan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 47 USPATFULL on STN

AN 2007:24544 USPATFULL <<LOGINID::20070823>>
TI Obesity-related genes
IN Collier, Greg, Ocean Grove, AUSTRALIA
Walder, Ken, Ocean Grove, AUSTRALIA
Segal, David, Ocean Grove, AUSTRALIA
Foletta, Victoria C., Ocean Grove, AUSTRALIA
PI US 2007021589 A1 20070125
AI US 2004-541998 A1 20040113 (10)
WO 2004-AU43 20040113
20060117 PCT 371 date
PRAI US 2003-60439767 20030113
DT Utility
FS APPLICATION
LREP SCULLY, SCOTT, MURPHY & PRESSER, 400 GARDEN CITY PLAZA, SUITE 300, GARDEN CITY, NY, 11530, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6460
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to a nucleic acid molecule which is expressed in at least red gastrocnemius muscle or its equivalent under particular physiological conditions. It is proposed that the nucleic acid molecule is differentially expressed under differing conditions of healthy state, myopathy, obesity, anorexia, weight maintenance, diabetes, disorders associated with mitochondrial dysfunction, genetic disorders, cancer, heart disease, inflammation, disorders associated with the immune system, infertility, disease associated with the brain and/or metabolic energy levels. The subject nucleic acid molecule and/or its expression product is proposed to be used in therapeutic and diagnostic protocols for conditions such as healthy state, myopathy, obesity, anorexia, weight maintenance, diabetes, disorders associated with mitochondrial dysfunction, genetic disorders, cancer, heart disease, inflammation, disorders associated with the immune system, infertility, disease associated with the brain and/or metabolic energy levels or as targets for the design and/or identification of modulators of their activity and/or function.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 47 USPATFULL on STN
AN 2007:17006 USPATFULL <<LOGINID::20070823>>
TI Steroid analogs and characterization and treatment methods
IN Reading, Christopher L., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
Dowding, Charles, San Diego, CA, UNITED STATES
PI US 2007014719 A1 20070118
AI US 2005-241670 A1 20050929 (11)
PRAI US 2004-614869P 20040929 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 24267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods to characterize exemplified compounds such as 3β, 17β-dihydroxyandrost-1,5,11 -triene and 3β, 17β-dihydroxy-17α-ethynylandrost-1,5,11-triene and to the use of described compounds to ameliorate or treat a condition such as thrombocytopenia, inflammation or other exemplified conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 47 USPATFULL on STN
AN 2006:268091 USPATFULL <<LOGINID::20070823>>
TI Differential expression of nucleic acid molecules
IN Collier, Greg Royce, Victoria, AUSTRALIA
Walder, Ken Russell, Victoria, AUSTRALIA
PA CHEMGENEX PHARMACEUTICALS LLIMITED (non-U.S. corporation)
PI US 2006228775 A1 20061012
AI US 2004-564077 A1 20040708 (10)
WO 2004-AU919 20040708
20060518 PCT 371 date
PRAI US 2003-485790P 20030708 (60)
DT Utility
FS APPLICATION
LREP DUANE MORRIS LLP, PATENT DEPARTMENT, 380 LEXINGTON AVENUE, NEW YORK, NY, 10168-0002, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1-46
DRWN 54 Drawing Page(s)
LN.CNT 6563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to nucleic acid molecules expressed at least in the hypothalamus, liver, mesenteric adipose tissue, or red gastrocnemius muscle conveniently identified using differential display techniques under differing physiological conditions. The nucleic acid molecules are associated with or act as markers for conditions of inter alia a healthy state, myopathy, obesity, anorexia, weight maintenance, diabetes, disorders associated with mitochondrial dysfunction, genetic disorders and/or metabolic energy levels. More particularly, the present invention is directed to a nucleic acid molecule and/or its expression product for use in therapeutic and diagnostic protocols for conditions such as inter alia a myopathy, obesity, anorexia, weight maintenance, diabetes, disorders associated with mitochondrial dysfunction, genetic disorders and/or metabolic energy levels. The subject nucleic acid molecule and expression product and their derivatives, homologs, analogs and mimetics are proposed to be useful, therefore, as therapeutic and diagnostic agents for inter alia a myopathy, obesity, anorexia, weight maintenance, diabetes, disorders associated with mitochondrial dysfunction, genetic disorders and/or metabolic energy levels or as targets for the design and/or identification of modulators of their activity and/or function.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 47 USPATFULL on STN
AN 2006:209367 USPATFULL <<LOGINID::20070823>>
TI Compounds for the treatment of inflammatory disorders
IN Siddiqui, M. Arshad, Newton, MA, UNITED STATES
Mansoor, Umar Faruk, Farmingham, MA, UNITED STATES
Reddy, Panduranga A., Walpole, MA, UNITED STATES
Madison, Vincent S., Mountain Lakes, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 2006178366 A1 20060810
AI US 2005-291595 A1 20051201 (11)
RLI Continuation-in-part of Ser. No. US 2005-142601, filed on 1 Jun 2005, PENDING
PRAI US 2004-576153P 20040602 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 13182
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compounds of the Formula (I): ##STR1## or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 47 USPATFULL on STN
AN 2006:208445 USPATFULL <<LOGINID::20070823>>
TI FcgammaRIIB-specific antibodies and methods of use thereof
IN Koenig, Scott, Rockville, MD, UNITED STATES
Veri, Maria Concetta, Denwood, MD, UNITED STATES
Tuaillon, Nadine, Gettysburg, PA, UNITED STATES
PI US 2006177439 A1 20060810
AI US 2005-305787 A1 20051215 (11)
PRAI US 2004-636663P 20041215 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 7150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 47 USPATFULL on STN
AN 2006:194947 USPATFULL <<LOGINID::20070823>>
TI Fixed dosing of HER antibodies
IN Allison, David E., San Mateo, CA, UNITED STATES
Bruno, Rene, Marseille, FRANCE
Lu, Jian-Feng, Foster City, CA, UNITED STATES
Ng, Chee M., San Mateo, CA, UNITED STATES
PA GENENTECH, INC. (U.S. corporation)
PI US 2006165702 A1 20060727
AI US 2005-154091 A1 20050615 (11)
PRAI US 2005-645697P 20050121 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 4674
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 47 USPATFULL on STN
AN 2006:143530 USPATFULL <<LOGINID::20070823>>
TI Selecting patients for therapy with a her inhibitor
IN Amler, Lukas C., Foster City, CA, UNITED STATES
Januario, Thomas E., San Francisco, CA, UNITED STATES
PA Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 2006121044 A1 20060608
AI US 2005-295229 A1 20051206 (11)
PRAI US 2004-633941P 20041207 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 4230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for selecting patients for therapy with a HER inhibitor, such as pertuzumab, based on gene expression analysis is described. A method for assessing HER phosphorylation or activation in a biological sample via gene expression analysis is also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 47 USPATFULL on STN
AN 2006:93361 USPATFULL <<LOGINID::20070823>>
TI Compositions and treatment methods
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND
PI US 2006079492 A1 20060413
AI US 2005-234675 A1 20050923 (11)
RLI Division of Ser. No. US 2002-87929, filed on 1 Mar 2002, PENDING
Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, ABANDONED
PRAI US 1999-161453P 19991025 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 18831
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 47 USPATFULL on STN

AN 2006:15432 USPATFULL <<LOGINID::20070823>>
TI Humanized FcgammaRIIB-specific antibodies and methods of use thereof
IN Johnson, Leslie S., Darnestown, MD, UNITED STATES
Huang, Ling, Gaithersburg, MD, UNITED STATES
PI US 2006013810 A1 20060119
AI US 2005-126978 A1 20050510 (11)
PRAI US 2004-569882P 20040510 (60)
US 2004-582043P 20040621 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 7393
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 47 USPATFULL on STN
AN 2005:312041 USPATFULL <<LOGINID::20070823>>
TI Preventing autoimmune disease
IN Brunetta, Paul G., San Francisco, CA, UNITED STATES
Grewal, Iqbal S., Mill Creek, WA, UNITED STATES
Walicke, Patricia A., Brisbane, CA, UNITED STATES
PA GENENTECH, INC. (U.S. corporation)
PI US 2005271658 A1 20051208
AI US 2005-120338 A1 20050503 (11)
PRAI US 2004-568460P 20040505 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
CLMN Number of Claims: 71
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 3475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes a method of preventing an autoimmune disease in an asymptomatic human subject at risk for experiencing one or more symptoms of the autoimmune disease, by administering a CD20 antibody to the subject in an amount to prevent the subject from experiencing one or more symptoms of the autoimmune disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 47 USPATFULL on STN
AN 2005:298549 USPATFULL <<LOGINID::20070823>>
TI Fcgamma-RIIB-specific antibodies and methods of use thereof
IN Koenig, Scott, Rockville, MD, UNITED STATES
Veri, Maria Concetta, Denwood, MD, UNITED STATES

Tuaillon, Nadine, Gettysburg, PA, UNITED STATES
Bonvini, Ezio, Rockville, MD, UNITED STATES
Stavenhagen, Jeffrey, Brookville, MD, UNITED STATES
Rankin, Christopher, Clarksburg, MD, UNITED STATES
PI US 2005260213 A1 20051124
AI US 2005-108135 A1 20050415 (11)
PRAI US 2004-562804P 20040416 (60)
US 2004-582044P 20040621 (60)
US 2004-582045P 20040621 (60)
US 2005-654713P 20050218 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 64
ECL Exemplary Claim: 1
DRWN 51 Drawing Page(s)
LN.CNT 9147
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 47 USPATFULL on STN
AN 2005:248567 USPATFULL <<LOGINID::20070823>>
TI Fcgamma riib specific antibodies and methods of use thereof
IN Koenig, Scott, Rockville, MD, UNITED STATES
Veri, Maria, Derwood, MD, UNITED STATES
PA MacroGenics Inc. (U.S. corporation)
PI US 2005215767 A1 20050929
AI US 2003-524134 A1 20030814 (10)
WO 2003-US25399 20030814
20050211 PCT 371 date
PRAI US 2002-403266P 20020814 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 107
ECL Exemplary Claim: 1
DRWN 29 Drawing Page(s)
LN.CNT 6922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering

the antibodies of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 47 USPATFULL on STN
AN 2005:240095 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005208095 A1 20050922
AI US 2004-996354 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 34089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 47 USPATFULL on STN
AN 2005:226572 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005196421 A1 20050908
AI US 2004-1417 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 100
ECL Exemplary Claim: 1-7300
DRWN 32 Drawing Page(s)
LN.CNT 34222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 22 OF 47 USPATFULL on STN
AN 2005:215464 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005187140 A1 20050825
AI US 2004-408 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2004-611077P 20040917 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-5846
DRWN 32 Drawing Page(s)
LN.CNT 34103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 23 OF 47 USPATFULL on STN
AN 2005:214572 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005186244 A1 20050825
AI US 2004-1790 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-8540
DRWN 32 Drawing Page(s)
LN.CNT 34060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 24 OF 47 USPATFULL on STN
AN 2005:212068 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005183731 A1 20050825
AI US 2004-6908 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1-8061
DRWN 32 Drawing Page(s)
LN.CNT 34032
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L9 ANSWER 25 OF 47 USPATFULL on STN
AN 2005:209978 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005182463 A1 20050818
AI US 2004-1788 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 125
ECL Exemplary Claim: 1-8059
DRWN 32 Drawing Page(s)
LN.CNT 34070
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L9 ANSWER 26 OF 47 USPATFULL on STN
AN 2005:205930 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005178396 A1 20050818
AI US 2004-6905 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1-8063
DRWN 32 Drawing Page(s)
LN.CNT 33965
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L9 ANSWER 27 OF 47 USPATFULL on STN
AN 2005:205929 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005178395 A1 20050818
AI US 2004-6900 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 58
ECL Exemplary Claim: 1-7302
DRWN 32 Drawing Page(s)
LN.CNT 34043
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage

loss.

L9 ANSWER 28 OF 47 USPATFULL on STN
AN 2005:202285 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175703 A1 20050811
AI US 2004-6888 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1-7576
DRWN 32 Drawing Page(s)
LN.CNT 33992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 29 OF 47 USPATFULL on STN
AN 2005:202247 USPATFULL <<LOGINID::20070823>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175665 A1 20050811
AI US 2004-6896 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1-7822
DRWN 32 Drawing Page(s)
LN.CNT 33978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 30 OF 47 USPATFULL on STN
AN 2005:152021 USPATFULL <<LOGINID::20070823>>
TI Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
IN Weidner, Morten Sloth, Virum, DENMARK
PI US 2005130935 A1 20050616
AI US 2003-512029 A1 20030422 (10)
WO 2003-DK263 20030422
PRAI PA 2002-200200586 20020419
US 2003-373615P 20020419 (60)
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1-53
DRWN No Drawings
LN.CNT 1427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to combinations of an aminosugar and a beta-2-adrenoceptor agonist, such as salbutamol, for the treatment of diseases associated with hypersensivity and inflamation, in particular hypersensivity skin diseases. The aminosugar is preferably a monosaccharide derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 31 OF 47 USPATFULL on STN
AN 2005:118308 USPATFULL <<LOGINID::20070823>>
TI Therapeutic treatment methods 2
IN Reading, Christopher L., San Diego, CA, UNITED STATES
Ahlem, Clarence N., San Diego, CA, UNITED STATES
Auci, Dominick L., San Diego, CA, UNITED STATES
Dowding, Charles, San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
Li, Mei, San Diego, CA, UNITED STATES
Page, Theodore M., Carlsbad, CA, UNITED STATES
Stickney, Dwight R., Granite Bay, CA, UNITED STATES
Trauger, Richard J., Leucadia, CA, UNITED STATES
White, Steven K., San Diego, CA, UNITED STATES
PI US 2005101581 A1 20050512
AI US 2003-728400 A1 20031205 (10)
RLI Continuation-in-part of Ser. No. US 2003-651515, filed on 28 Aug 2003, PENDING

PRAI US 2002-407146P 20020828 (60)
US 2002-408332P 20020904 (60)
US 2003-479257P 20030617 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 18638
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 32 OF 47 USPATFULL on STN
AN 2004:334244 USPATFULL <<LOGINID::20070823>>
TI Soluble FcgammaR fusion protiens and methods of use thereof
IN Johnson, Leslie S., Darnstown, MD, UNITED STATES
Li, Hua, Gaithersburg, MD, UNITED STATES
Tuaillon, Nadine, Gettysburg, PA, UNITED STATES
PI US 2004265321 A1 20041230
AI US 2004-756153 A1 20040113 (10)
PRAI US 2003-439709P 20030113 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 6742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an FcγR, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 33 OF 47 USPATFULL on STN
AN 2004:253906 USPATFULL <<LOGINID::20070823>>
TI Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals

IN Henderson, Todd R., Jarrettsville, MD, UNITED STATES
Hammad, Tarek, Baltimore, MD, UNITED STATES
Soliman, Medhat, Minya, EGYPT
Corson, Barbara, Fawn Grove, PA, UNITED STATES
Lippiello, Louis, Forest Hill, MD, UNITED STATES
Henderson, Robert, Baldwin, MD, UNITED STATES
PA NUTRAMAX LABORATORIES, INC., Edgewood, MD, UNITED STATES (U.S. corporation)
PI US 2004197431 A1 20041007
AI US 2004-824498 A1 20040415 (10)
RLI Continuation of Ser. No. US 2002-192318, filed on 11 Jul 2002, PENDING
Continuation of Ser. No. US 1999-274881, filed on 23 Mar 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-249335, filed on 12 Feb 1999, GRANTED, Pat. No. US 6451771
PRAI US 1998-74594P 19980213 (60)
US 1998-88205P 19980605 (60)
DT Utility
FS APPLICATION
LREP COVINGTON & BURLING, ATTN: PATENT DOCKETING, 1201 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC, 20004-2401
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1145
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 34 OF 47 USPATFULL on STN
AN 2004:239241 USPATFULL <<LOGINID::20070823>>
TI FcgammaRIIB-specific antibodies and methods of use thereof
IN Koenig, Scott, Rockville, MD, UNITED STATES
Veri, Maria Concetta, Derwood, MD, UNITED STATES
PA MacroGenics, Inc. (U.S. corporation)
PI US 2004185045 A1 20040923
AI US 2003-643857 A1 20030814 (10)
PRAI US 2002-403266P 20020814 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
CLMN Number of Claims: 107
ECL Exemplary Claim: 1
DRWN 29 Drawing Page(s)
LN.CNT 7320
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 35 OF 47 USPATFULL on STN
AN 2004:179017 USPATFULL <<LOGINID::20070823>>
TI Therapeutic treatment methods
IN Reading, Christopher L., San Diego, CA, UNITED STATES
Ahlem, Clarence N., San Diego, CA, UNITED STATES
Auci, Dominick L., San Diego, CA, UNITED STATES
Dowding, Charles, San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
Li, Mei, San Diego, CA, UNITED STATES
Page, Theodore M., Carlsbad, CA, UNITED STATES
Stickney, Dwight R., Granite Bay, CA, UNITED STATES
Trauger, Richard J., Leucadia, CA, UNITED STATES
White, Steven K., San Diego, CA, UNITED STATES
PI US 2004138187 A1 20040715
AI US 2003-651515 A1 20030828 (10)
PRAI US 2002-407146P 20020828 (60)
US 2002-408332P 20020904 (60)
US 2003-479257P 20030617 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 16128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 36 OF 47 USPATFULL on STN
AN 2003:288217 USPATFULL <<LOGINID::20070823>>
TI Reagents and treatment methods for autoimmune diseases
IN Tedder, Thomas F., Durham, NC, UNITED STATES
PI US 2003202975 A1 20031030
AI US 2003-372481 A1 20030221 (10)
PRAI US 2002-359419P 20020221 (60)
US 2002-420472P 20021021 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 1749
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular,

the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 37 OF 47 USPATFULL on STN
AN 2003:232531 USPATFULL <<LOGINID::20070823>>
TI Combination of aminosugars and cysteine or cysteine derivatives
IN Weidner, Morten Sloth, Virum, DENMARK
PA Astion Development A/S, Kobenhavn, DENMARK (non-U.S. corporation)
PI US 2003162732 A1 20030828
AI US 2002-185982 A1 20020628 (10)
PRAI US 2001-303298P 20010705 (60)
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to chemical complexes consisting of cysteine or derivatives of cysteine and an aminosugar as well as pharmaceutical compositions and dietary supplements comprising such complexes. The invention further relates to the use of such compositions or complexes for the preparation of a medicament or a dietary supplement in the suppression of hypersensitivity and inflammatory reactions such as rheumatic or dermatological disorders or to a method of treating such diseases by administering such compositions and complexes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 38 OF 47 USPATFULL on STN
AN 2003:187474 USPATFULL <<LOGINID::20070823>>
TI Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
IN Henderson, Todd R., Jarrettsville, MD, UNITED STATES
Hammad, Tarek, Baltimore, MD, UNITED STATES
Soliman, Medhat, Minya, EGYPT
Corson, Barbara E., Fawn Grove, PA, UNITED STATES
Lippiello, Louis, Forest Hill, MD, UNITED STATES
Henderson, Robert W., Baldwin, MD, UNITED STATES
PI US 2003129261 A1 20030710
US 6797289 B2 20040928
AI US 2002-192318 A1 20020711 (10)
RLI Continuation of Ser. No. US 1999-274881, filed on 23 Mar 1999, PENDING
Continuation-in-part of Ser. No. US 1999-249335, filed on 12 Feb 1999, GRANTED, Pat. No. US 6451771
PRAI US 1998-88205P 19980605 (60)
US 1998-74594P 19980213 (60)
DT Utility
FS APPLICATION
LREP Covington & Burling, 1201 Pennsylvania Avenue, NW, Washington, DC, 20004-2401
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 39 OF 47 USPATFULL on STN
AN 2003:120747 USPATFULL <<LOGINID::20070823>>
TI Blood cell deficiency treatment method
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND
PI US 2003083231 A1 20030501
AI US 2002-87929 A1 20020301 (10)
RLI Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED
PRAI US 1999-161453P 19991025 (60)
US 2001-272624P 20010301 (60)
US 2001-323016P 20010911 (60)
US 2001-340045P 20011130 (60)
US 2001-328738P 20011011 (60)
US 2001-338015P 20011108 (60)
US 2001-343523P 20011220 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-109923P 19981124 (60)
US 1998-109924P 19981124 (60)
US 1998-110127P 19981127 (60)
US 1998-112206P 19981215 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1999-140028P 19990616 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of compounds to treat a

number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 40 OF 47 USPATFULL on STN
AN 2003:86817 USPATFULL <<LOGINID::20070823>>
TI Immune modulation method using steroid compounds
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES
PI US 2003060425 A1 20030327
AI US 2001-820483 A1 20010329 (9)
RLI Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED
PRAI US 1998-109924P 19981124 (60)
US 1999-140028P 19990616 (60)
US 1998-109923P 19981124 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-110127P 19981127 (60)
US 1999-161453P 19991025 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1998-112206P 19981215 (60)
US 2000-257071P 20001220 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 14708
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3 β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen

replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 41 OF 47 USPATFULL on STN
AN 2002:280085 USPATFULL <<LOGINID::20070823>>
TI Human blood bacterium
IN Lindner, Luther E., College Station, TX, UNITED STATES
MacPhee, Kathleen, Spring, TX, UNITED STATES
PA Pathobiotek Diagnostics Inc. (U.S. corporation)
PI US 2002155519 A1 20021024
AI US 2001-894467 A1 20010628 (9)
RLI Division of Ser. No. US 1998-187946, filed on 2 Nov 1998, PATENTED
PRAI US 1997-64472P 19971106 (60)
DT Utility
FS APPLICATION
LREP Dr. Benjamin Adler, Adler & Associates, 8011 Candle Lane, Houston, TX, 77071
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2179
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention reports a newly-identified human blood bacterium (HBB), provides characterization, culturing and diagnostic methodologies therefor and methods for the treatment of pathophysiological states caused by the bacterium. The bacterium is apparently present in the bloodstream of all humans in very low numbers, and appears to be directly or indirectly associated with several diseases such as chronic fatigue syndrome, multiple sclerosis and other "autoimmune" diseases. Also provided are uses of engineered HBB.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 42 OF 47 USPATFULL on STN
AN 2002:221807 USPATFULL <<LOGINID::20070823>>
TI USEOF ANABOLIC AGENTS ANTI-CATABOLIC AGENTS AND ANTIOXIDANT AGENTS FOR PROTECTION TREATMENT AND REPAIR OF CONNECTIVE TISSUES IN HUMANS AND ANIMALS
IN HENDERSON, TODD R. DVM, JARRETSVILLE, MD, UNITED STATES
CORSON, BARBARA E.RN. DVM, FAWN GROVE, PA, UNITED STATES
HAMMAD, TAREK, BALTIMORE, MD, UNITED STATES
SOLIMAN, MEDHAT, MINYA, EGYPT
LIPPIELLO, LOUIS, SCOTTSDALE, AZ, UNITED STATES
PI US 2002119950 A1 20020829
US 6451771 B2 20020917
AI US 1999-249335 A1 19990212 (9)
DT Utility
FS APPLICATION
LREP COVINGTON & BURLING, ATTN: PATENT DOCKETING, 1201 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC, 20004-2401
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, and anti-oxidant agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, pentosan, collagen type II, tetracyclines or tetracycline-like

compounds, diacerin, super oxide dismutase, and L-ergothionine and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 43 OF 47 USPATFULL on STN
AN 2001:194409 USPATFULL <<LOGINID::20070823>>
TI Chemical complex comprising a substituted pyridine carboxy derivative and a glucosaminoglycan
IN Weidner, Morten Sloth, Virum, Denmark
PI US 2001036924 A1 20011101
AI US 2001-813723 A1 20010321 (9)
PRAI DK 2000-467 20000321
US 2000-191689P 20000323 (60)
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1387
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a chemical composition comprising an optionally substituted pyridine carboxy derivative and a glucosaminoglycan and a pharmaceutical composition or a dietary supplement comprising an optionally substituted pyridine carboxy derivative and a glucosaminoglycan and to the use of such compositions for the preparation of a medicament or a dietary supplement for immunomodulation in a mammal and the suppression of hypersensitivity and/or inflammatory reaction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 44 OF 47 USPATFULL on STN
AN 2001:102976 USPATFULL <<LOGINID::20070823>>
TI Human blood bacterium
IN Lindner, Luther E., College Station, TX, United States
MacPhee, Kathleen, Spring, TX, United States
PA Pathobiotek Diagnostics Inc., The Woodlands, TX, United States (U.S. corporation)
PI US 6255467 B1 20010703
AI US 1998-187946 19981102 (9)
PRAI US 1997-64472P 19971106 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Smith, Lynette R. F.; Assistant Examiner: Lee, Li
LREP Adler, Benjamin Aaron
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention reports a newly-identified human blood bacterium (HBB), provides characterization, culturing and diagnostic methodologies therefor and methods for the treatment of pathophysiological states caused by the bacterium. The bacterium is apparently present in the bloodstream of all humans in very low numbers, and appears to be directly or indirectly associated with several diseases such as chronic fatigue syndrome, multiple sclerosis and other "autoimmune" diseases. Also provided are uses of engineered HBB.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 45 OF 47 USPAT2 on STN
AN 2003:187474 USPAT2 <<LOGINID::20070823>>
TI Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
IN Henderson, Todd R., Jarrettsville, MD, United States
Hammad, Tarek, Baltimore, MD, United States
Soliman, Medhat, Minya, EGYPT
Corson, Barbara, Fawn Grove, PA, United States.
Henderson, Robert, Baldwin, MD, United States
PA Nutramax Laboratories, Inc., Edgewood, MD, United States (U.S. corporation)
PI US 6797289 B2 20040928
AI US 2002-192318 20020711 (10)
RLI Continuation of Ser. No. US 1999-274881, filed on 23 Mar 1999
Continuation-in-part of Ser. No. US 1999-249335, filed on 12 Feb 1999, now patented, Pat. No. US 6451771
PRAI US 1998-88205P 19980605 (60)
US 1998-74594P 19980213 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wang, Shengjun
LREP Covington & Burling
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 46 OF 47 USPAT2 on STN
AN 2002:221807 USPAT2 <<LOGINID::20070823>>
TI Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
IN Henderson, Todd R., Jarrettsville, MD, United States
Corson, Barbara E., Fawn Grove, PA, United States
Hammad, Tarek, Baltimore, MD, United States
Soliman, Medhat, Minya, EGYPT
Lippiello, Louis, Scottsdale, AZ, United States
PA Nutramax Laboratories, Inc., Edgewood, MD, United States (U.S. corporation)
PI US 6451771 B2 20020917
AI US 1999-249335 19990212 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Travers, Russell
LREP Covington & Burling
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, and anti-oxidant agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, and L-ergothionine and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 47 OF 47 WPINDEX COPYRIGHT 2007 THE THOMSON CORP on STN
AN 2003-778264 [73] WPINDEX <<LOGINID::20070823>>
DNC C2003-214136 [73]
TI Complex useful in suppression of hypersensitivity and inflammatory reactions for treatment of e.g. rheumatic disorder, comprises cysteine derivative and optionally substituted amino sugar or their salts
DC A96; B04; B05; D13; D21
IN WEIDNER M S
PA (ASTI-N) ASTION DEV AS
CYC 1
PIA US 20030162732 A1 20030828 (200373)* EN 24[0]
ADT US 20030162732 A1 Provisional US 2001-303298P 20010705; US 20030162732 A1 US 2002-185982 20020628
PRAI US 2002-185982 20020628
US 2001-303298P 20010705
AN 2003-778264 [73] WPINDEX <<LOGINID::20070823>>
AB US 20030162732 A1 UPAB: 20060120
NOVELTY - Complex comprises at least one cysteine derivative (I) and at least one optionally substituted amino sugar or their salts.

DETAILED DESCRIPTION - A complex comprises at least one cysteine derivative of formula (I), and at least one optionally substituted amino sugar (II), or their salts.

RN = 1-8C alkyl, 2-10C alkenyl, 2-10C alkynyl, 3-7C cycloalkyl or 1-8C acyl (all optionally substituted) or H;

R1 = OR3, SR3, halo or N(RN)RN;

Rs = 1-6C alkyl, 1-6C alkenyl, 2-6C alkynyl, 1-8C acyl or 3-7C cycloalkyl (all optionally substituted), H, sulfate or a cysteine derivative of formula (I); and

R3 = not defined.

Provided that the composition is essentially free of vitamin C.

ACTIVITY - Antirheumatic; Antiarthritic; Osteopathic; Antiinflammatory; Uropathic; Ophthalmological; Antipsoriatic; Dermatological; Antiseborrheic; Antipruritic; Endocrine-Gen.; Antiasthmatic; Antiallergic; Immunosuppressive; Antidiabetic; Antithyroid; Antianemic; Hepatotropic; Analgesic; Cytostatic; Muscular-Gen.; Neuroprotective. Male SPF Sprague Dawley rats (80 - 100 g) were randomly allocated to groups, each of 12 rats. A complex of N-acetylcysteine (4 mole) and glucosamine potassium sulfate salt (3 mole) was administered intraperitoneally in volume of 20 ml/kg, once daily on day -2 and -1 to groups 2, 3 and 4 only, and on day 0 to groups 2 - 6, 0 - 5 minutes before injection of carrageenin into the foot on day 0. Ibuprofen and vehicle were administered orally by gavage in volume of 20 mg/kg on day 0, 0 - 5 minutes before injection of the carrageenin into the foot. After three hours an inhibition of 40, 63 and 50% of paw oedema was seen after 100, 333 and 1000 mg/kg of the complex given for three days, respectively. Ibuprofen at dose levels of 50 and 150 mg/kg inhibited 37 and 57% respectively.

MECHANISM OF ACTION - None Given.

USE - For suppression or hypersensitivity and/or inflammatory reactions for the treatment of rheumatic disease (e.g. rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Reiter's syndrome, psoriatic arthritis, juvenile chronic arthritis, enteropathic synovitis, infective arthritis, soft tissue rheumatism and fibromyalgia),

chondroprotection or repair of articular cartilage, skin disease (e.g. atopic dermatitis, contact dermatitis, seborrhoeic dermatitis, pruritus, nodular prurigo (prurigo nodularis hyde), urticaria, acne, rosacea, alopecia, vitiligo and psoriasis), IgE mediated allergic reactions (e.g. asthma, allergic rhinitis, allergic conjunctivitis and anaphylaxis), autoimmune disease and/or chronic inflammatory disease, diabetes, Crohn's disease, lupus erythematosus, scleroderma, Sjogren's syndrome, Grave's disease, Pernicious anemia, autoimmune hepatitis, pemphigus vulgaris, pemphigus, foliaceus, bullous pemphigoid, Myasthenia gravis and rheumatoid arthritis (all claimed). Also for the reduction in pain e.g. muscle pain and suppression cancer; and for the treatment of hypersensitivity related insect bites, allergic vasculitis, post-operative reactions and transplant rejection.

ADVANTAGE - The composition dose not additionally contains non-steroid antiinflammatory agent and free of dietary constituent that forms part of the daily food intake e.g. vitamin C. The composition is free of excipients such as magnesium salt (e.g. magnesium ascorbate, magnesium taurate, magnesium citrate or magnesium oxide). The complex provides anti-hypersensitivity and anti-inflammatory effect with a good safety profile.

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   190.30     190.51

FILE 'CAPLUS' ENTERED AT 15:16:54 ON 23 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 23 Aug 2007  VOL 147 ISS 9
FILE LAST UPDATED: 22 Aug 2007  (20070822/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s Xu Qiwang/AU
L10         33 XU QIWANG/AU

=> s l10 and N-acetylglucosamine
       3073272 N
         12718 ACETYLGLUCOSAMINE
            58 ACETYLGLUCOSAMINES
         12744 ACETYLGLUCOSAMINE
                 (ACETYLGLUCOSAMINE OR ACETYLGLUCOSAMINES)
         11481 N-ACETYLGLUCOSAMINE
                 (N(W)ACETYLGLUCOSAMINE)
L11          1 L10 AND N-ACETYLGLUCOSAMINE
```

```
=> s l10 and N-acetyl-D-glucosamine
       3073272 N
        161766 ACETYL
            68 ACETYLS
        161802 ACETYL
                 (ACETYL OR ACETYLS)
       2482826 D
         22201 GLUCOSAMINE
           328 GLUCOSAMINES
         22304 GLUCOSAMINE
                 (GLUCOSAMINE OR GLUCOSAMINES)
          2882 N-ACETYL-D-GLUCOSAMINE
                 (N(W)ACETYL(W)D(W)GLUCOSAMINE)
L12          14 L10 AND N-ACETYL-D-GLUCOSAMINE

=> dis l12 1-14 bib abs

L12  ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:425901  CAPLUS <<LOGINID::20070823>>
DN   144:419764
TI   Antibacterial compositions of N-acetyl-d-aminoglycosamine and antibiotics
IN   Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA   Third Military Medical University, Chinese People's Liberation Army P.R.
     Of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New
     District Corporation, Ltd.
SO   PCT Int. Appl., 41 pp.
     CODEN: PIXXD2
DT   Patent
LA   Chinese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.      DATE
     --------------      ----   --------    -------------------  --------
PI   WO 2005025582        A1    20050324    WO 2003-CN793        20030918
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003271022         A1    20050406    AU 2003-271022       20030918
     EP 1669077            A1    20060614    EP 2003-750251       20030918
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK
     BR 2003018497         A     20060912    BR 2003-18497        20030918
     US 2007191291         A1    20070816    US 2007-572226       20070221
PRAI CN 2003-108279        A     20030327
     WO 2003-CN793         W     20030918
AB   The use of the combination of N-acetyl-D-
     glucosamine and antibiotics is disclosed, for the preparation of
     antibacterial drugs.  In the therapies with antibacterial drugs, the
     pathogens may be changed into cryptic growth cells (CGCs), CGCs can
     colonize and thereby drug resistance arises.  In the meantime, normal
     bacteria colonies in the body may be also changed into CGCs.  These
     changes result in complications after the therapies, such as disorder of
     bacteria colonies in the body, disorder of GI functions and other chronic
     diseases.  The combination of antibiotics and N-Acetyl-D-Aminoglycosamine
     can prevent of CGC, and the complications after antibiotics therapy.  For
     example, i.m. injections contained N-acetyl-d-aminoglycosamine and
     kanamycin can prevent the GI tract bacteria changed into CGCs.
```

L12 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1008183 CAPLUS <<LOGINID::20070823>>
DN 142:204729
TI Compounded antibacterial agent of N-acetyl-D -glucosamine and antibiotics for intestinal disorders
IN Xu, Qiwang; Liu, Junkang
PA The Third Military Medical University of PLA, Peop. Rep. China; Bawei Medicine Development Institute Co., Ltd., Suzhou
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 33 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1471920	A	20040204	CN 2002-127150	20020729
PRAI	CN 2002-127150		20020729		

AB The invention relates to the application of compounded antibacterial agent of N-acetyl-D-glucosamine and antibiotics (such as aminoglycoside, macrolide, tetracyclines, quinolones, lincomycins, chloramphenicols, cephalosporins, penicillins, or other beta-lactams) to prepare the medical prepns. (such as injection, tablet, capsule, etc.) for preventing and treating irritable bowel syndrome, in vivo dysbacteriosis, intestinal function disorder, etc.

L12 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1007939 CAPLUS <<LOGINID::20070823>>
DN 142:148819
TI Application of N-acetyl-D-glucosamine to prepare medical preparation for regulating micro-ecological balance of skin mucosa
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA The Third Military Medical University of PLA, Peop. Rep. China; Bawei Medicine Development Institute Co., Ltd., Suzhou
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 8 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1470244	A	20040128	CN 2002-126833	20020722
PRAI	CN 2002-126833		20020722		

AB The invention relates to the application of N-acetyl-D-glucosamine to prepare medical prepns. (such as aqua preparation, emulsion, spray, cream, or ointment) for regulating micro-ecol. balance of skin mucosa.

L12 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1007938 CAPLUS <<LOGINID::20070823>>
DN 142:148766
TI Application of N-acetyl-D-glucosamine to prepare the medical preparation for treating neoplasm and metastasis of neoplasm
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA The Third Military Medical University of PLA, Peop. Rep. China; Bawei Medicine Development Institute Co., Ltd., Suzhou
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 8 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI CN 1470243 A 20040128 CN 2002-126831 20020722
PRAI CN 2002-126831 20020722
AB The invention relates to the application of N-acetyl-D-glucosamine to prepare the medical prepns. (such as injection, tablet, or capsule) for treating neoplasm and metastasis of neoplasm.

L12 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:142978 CAPLUS <<LOGINID::20070823>>
DN 140:175112
TI The use of N-acetyl-D-glucosamine for preparing medicines for urogenital tract infection treatment and prevention
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army P.R. of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014398	A1	20040219	WO 2003-CN664	20030813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1475217	A	20040218	CN 2002-125486	20020813
CA 2495684	A1	20040219	CA 2003-2495684	20030813
AU 2003255111	A1	20040225	AU 2003-255111	20030813
EP 1535620	A1	20050601	EP 2003-783908	20030813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006142243	A1	20060629	US 2005-524476	20051011
PRAI CN 2002-125486	A	20020813		
WO 2003-CN664	W	20030813		

AB The use of N-acetyl-D-glucosamine for preparing medicines for the treatment and prevention in urogenital tract infection is disclosed. N-acetyl-D-glucosamine can resist the homing of external microorganism and can further facilitate the rehabilitation of local skin tissue. The easily prepared formulation which mainly comprising N-acetyl-D-glucosamine can be used for urogenital tract infection treatment and prevention. The use of said formulation is effective and not-irritative, and does not lead to pollution.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675848 CAPLUS <<LOGINID::20070823>>
DN 137:195598
TI Application of N-acetyl-D-glucosamine in manufacturing drug for treating cardio-cerebrovascular ischemia
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao

PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002067949	A1	20020906	WO 2002-CN123	20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1372934	A	20021009	CN 2001-104893	20010228
AU 2002237183	A1	20020912	AU 2002-237183	20020228
US 2004106577	A1	20040603	US 2004-469213	20040112
US 7074774	B2	20060711		
PRAI CN 2001-104893	A	20010228		
WO 2002-CN123	W	20020228		

AB The present invention disclose the use of N-acetyl-D-glucosamine in the manufacture of drug for treating cardio-cerebrovascular ischemia and anoxia. N-acetyl-D-glucosamine is able to prolong the life time of exptl. animal under the condition of cerebrovascular ischemia and the environment of normal pressure and oxygen deficit, to reduce the degree of cerebral edema after reperfusion in cerebrovascular ischemia and the other symptom of neural behavior. The dosage form of this drug can be injection, tablet or capsule.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675847 CAPLUS <<LOGINID::20070823>>
DN 137:195621
TI Application of N-acetyl-D-glucosamine in manufacturing drug for preventing and treating sexual disorder
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002067948	A1	20020906	WO 2002-CN122	20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CN 1372930	A	20021009	CN 2001-104883	20010228
	CN 1131037	B	20031217		
	AU 2002235706	A1	20020912	AU 2002-235706	20020228
	EP 1371371	A1	20031217	EP 2002-702210	20020228
	EP 1371371	B1	20060614		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004522783	T	20040729	JP 2002-567315	20020228
	US 2004092483	A1	20040513	US 2004-469325	20040105
	US 7015207	B2	20060321		
PRAI	CN 2001-104883	A	20010228		
	WO 2002-CN122	W	20020228		

AB The present invention discloses the use of N-acetyl-D-glucosamine in manufacturing drug for preventing and treating sexual disorder. The formulation comprising of N-acetyl-D-glucosamine as main active ingredient is useful for preventing and treating sexual disorder with notable effect, convenient formulation and less side-effects. Its dosage form can be oral liqs., tincture or capsule.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675846 CAPLUS <<LOGINID::20070823>>
DN 137:195620
TI Application of N-acetyl-D-glucosamine in manufacturing drug for adjuvant treatment of perianal diseases
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067947	A1	20020906	WO 2002-CN120	20020228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1372932	A	20021009	CN 2001-104885	20010228
	CN 1131038	B	20031217		
	AU 2002235705	A1	20020912	AU 2002-235705	20020228
	US 2005119224	A1	20050602	US 2003-469284	20020228
PRAI	CN 2001-104885	A	20010228		
	WO 2002-CN120	W	20020228		

AB The present invention disclose the application of N-acetyl-D-glucosamine in manufacturing drug for adjuvant treatment of perianal diseases. By stabilizing membrane of cyto-lysosome, N-acetyl-D-glucosamine is able to suppress expansion of injury due to various enzyme releasing from cyto-lysosome, to promote healing of injured tissue; to inhibit localization and reproduction of organism at trauma and to control infection of organism. The formulation comprising of N-

acetyl-D-glucosamine as main active ingredient is useful for adjuvant treatment of perianal diseases with significant effect.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675845 CAPLUS <<LOGINID::20070823>>
DN 137:195619
TI Application of N-acetyl-D-glucosamine in manufacturing drug for suppressing side-effects of radiotherapy and chemotherapy
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067946	A1	20020906	WO 2002-CN119	20020228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1372929	A	20021009	CN 2001-104882	20010228
	CN 1131036	B	20031217		
	AU 2002237181	A1	20020912	AU 2002-237181	20020228
	EP 1374873	A1	20040102	EP 2002-703474	20020228
	EP 1374873	B1	20050427		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AT 293983	T	20050515	AT 2002-703474	20020228
	US 2004077596	A1	20040422	US 2003-469327	20031217
	US 7037904	B2	20060502		
	HK 1061530	A1	20051118	HK 2004-104522	20040624
PRAI	CN 2001-104882	A	20010228		
	WO 2002-CN119	W	20020228		

AB The present invention discloses the application of N-acetyl-D-glucosamine in manufacturing drug for suppressing side-effects of radiotherapy and chemotherapy. The formulation comprising of N-acetyl D-glucosamine as main active ingredient is used in tumor patients for suppressing side-effects of radiotherapy and chemotherapy with total efficiency is up to 85%. Its dosage form can be oral liqs. or injection.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675844 CAPLUS <<LOGINID::20070823>>
DN 137:195618
TI Application of N-acetyl-D-glucosamine in manufacturing drug for treating uterus cervical erosion
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army,

P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.

SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2

DT Patent

LA Chinese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002067945	A1	20020906	WO 2002-CN118	20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1372931	A	20021009	CN 2001-104884	20010228
AU 2002235704	A1	20020912	AU 2002-235704	20020228
US 2004138174	A1	20040715	US 2004-469268	20040302
US 6992073	B2	20060131		
PRAI CN 2001-104884	A	20010228		
WO 2002-CN118	W	20020228		

AB The present invention disclose the application of N-acetyl-D-glucosamine in manufacturing drug for treating cervical erosion. N-acetyl-D-glucosamine is able to suppress the localization and reproduction of organism, to control infection of organism, to ameliorate local exudation, inflammatory edema of tissue and pain etc. Its dosage form can be liqs., emulsion, suppository, ointment, and cream.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:675843 CAPLUS <<LOGINID::20070823>>

DN 137:195617

TI Application of N-acetyl-D-glucosamine in manufacturing drug for treating motion sickness

IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao

PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.

SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2

DT Patent

LA Chinese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002067944	A1	20020906	WO 2002-CN117	20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1372933	A	20021009	CN 2001-104892	20010228
AU 2002237180	A1	20020912	AU 2002-237180	20020228
US 2004116383	A1	20040617	US 2004-469326	20040203

	US 6946452	B2	20050920
PRAI	CN 2001-104892	A	20010228
	WO 2002-CN117	W	20020228

AB The present invention discloses the application of N-acetyl-D-glucosamine in manufacturing drug for treating motion sickness. The formulation comprising of N-acetyl-D-glucosamine as main active ingredient can be used in the prophylaxis and treatment of motion sickness with more than 90% efficiency. Its dosage form can be oral liquid or tablet.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:803380 CAPLUS <<LOGINID::20070823>>
DN 132:9035
TI Application of N-acetyl-D-glucosamine for preparing skin sanitary preparations
IN Xu, Qiwang
PA No.3 Army Medical Univ., Pla, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 8 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1156028	A	19970806	CN 1996-117868	19961227
	CN 1067246	B	20010620		
PRAI	CN 1996-117868		19961227		

AB Aminoglucose derivative N-acetyl-D-glucosamine is used for preparing skin sanitary prepns. The preparation is prepared with the traditional method to obtain solns., creams, emulsions, or pastes.

L12 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:803379 CAPLUS <<LOGINID::20070823>>
DN 132:9023
TI Application of N-acetyl-D-glucosamine in medicinal preparations for curing intestinal disease
IN Xu, Qiwang
PA No.3 Army Medical Univ., Pla, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 7 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1156027	A	19970806	CN 1996-117867	19961227
	CN 1095366	B	20021204		
PRAI	CN 1996-117867		19961227		

AB N-acetyl-D-glucosamine is claimed for treatment of intestinal disease. N-acetyl--glucosamine can be formulated into any dosage forms.

L12 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:803378 CAPLUS <<LOGINID::20070823>>
DN 132:8993
TI Application of N-acetyl-D-glucosamine in medicinal preparations for curing respiratory tract disease
IN Xu, Qiwang
PA No.3 Army Medical Univ., Pla, Peop. Rep. China

```
SO   Faming Zhuanli Shenqing Gongkai Shuomingshu, 6 pp.
     CODEN: CNXXEV
DT   Patent
LA   Chinese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   CN 1156026           A     19970806    CN 1996-117865         19961227
     CN 1067245           B     20010620
PRAI CN 1996-117865               19961227
AB   N-acetyl-D-glucosamine is used for
     treatment of respiratory tract diseases from bacterial infections.  The
     medicinal prepns. can be formulated into any dosage forms.


=> s Liu Junkang/AU
L13         45 LIU JUNKANG/AU

=> s l13 and N-acetyl-D-glucosamine
       3073272 N
        161766 ACETYL
            68 ACETYLS
        161802 ACETYL
                  (ACETYL OR ACETYLS)
       2482826 D
         22201 GLUCOSAMINE
           328 GLUCOSAMINES
         22304 GLUCOSAMINE
                  (GLUCOSAMINE OR GLUCOSAMINES)
          2882 N-ACETYL-D-GLUCOSAMINE
                  (N(W)ACETYL(W)D(W)GLUCOSAMINE)
L14           11 L13 AND N-ACETYL-D-GLUCOSAMINE

=> dis l14 1-11 bib abs

L14  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:425901  CAPLUS <<LOGINID::20070823>>
DN   144:419764
TI   Antibacterial compositions of N-acetyl-d-aminoglycosamine and antibiotics
IN   Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA   Third Military Medical University, Chinese People's Liberation Army P.R.
     Of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New
     District Corporation, Ltd.
SO   PCT Int. Appl., 41 pp.
     CODEN: PIXXD2
DT   Patent
LA   Chinese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005025582        A1    20050324    WO 2003-CN793          20030918
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003271022         A1    20050406    AU 2003-271022         20030918
     EP 1669077            A1    20060614    EP 2003-750251         20030918
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK

	BR 2003018497	A	20060912	BR 2003-18497	20030918
	US 2007191291	A1	20070816	US 2007-572226	20070221
PRAI	CN 2003-108279	A	20030327		
	WO 2003-CN793	W	20030918		

AB The use of the combination of N-acetyl-D-glucosamine and antibiotics is disclosed, for the preparation of antibacterial drugs. In the therapies with antibacterial drugs, the pathogens may be changed into cryptic growth cells (CGCs), CGCs can colonize and thereby drug resistance arises. In the meantime, normal bacteria colonies in the body may be also changed into CGCs. These changes result in complications after the therapies, such as disorder of bacteria colonies in the body, disorder of GI functions and other chronic diseases. The combination of antibiotics and N-Acetyl-D-Aminoglycosamine can prevent of CGC, and the complications after antibiotics therapy. For example, i.m. injections contained N-acetyl-d-aminoglycosamine and kanamycin can prevent the GI tract bacteria changed into CGCs.

L14 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1008183 CAPLUS <<LOGINID::20070823>>
DN 142:204729
TI Compounded antibacterial agent of N-acetyl-D-glucosamine and antibiotics for intestinal disorders
IN Xu, Qiwang; Liu, Junkang
PA The Third Military Medical University of PLA, Peop. Rep. China; Bawei Medicine Development Institute Co., Ltd., Suzhou
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 33 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1471920	A	20040204	CN 2002-127150	20020729
PRAI	CN 2002-127150		20020729		

AB The invention relates to the application of compounded antibacterial agent of N-acetyl-D-glucosamine and antibiotics (such as aminoglycoside, macrolide, tetracyclines, quinolones, lincomycins, chloramphenicols, cephalosporins, penicillins, or other beta-lactams) to prepare the medical prepns. (such as injection, tablet, capsule, etc.) for preventing and treating irritable bowel syndrome, in vivo dysbacteriosis, intestinal function disorder, etc.

L14 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1007939 CAPLUS <<LOGINID::20070823>>
DN 142:148819
TI Application of N-acetyl-D-glucosamine to prepare medical preparation for regulating micro-ecological balance of skin mucosa
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA The Third Military Medical University of PLA, Peop. Rep. China; Bawei Medicine Development Institute Co., Ltd., Suzhou
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 8 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1470244	A	20040128	CN 2002-126833	20020722
PRAI	CN 2002-126833		20020722		

AB The invention relates to the application of N-acetyl-D-glucosamine to prepare medical prepns. (such as aqua preparation, emulsion, spray, cream, or ointment) for regulating micro-ecol.

balance of skin mucosa.

L14 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1007938 CAPLUS <<LOGINID::20070823>>
DN 142:148766
TI Application of N-acetyl-D-glucosamine to prepare the medical preparation for treating neoplasm and metastasis of neoplasm
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA The Third Military Medical University of PLA, Peop. Rep. China; Bawei Medicine Development Institute Co., Ltd., Suzhou
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 8 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1470243	A	20040128	CN 2002-126831	20020722
PRAI	CN 2002-126831		20020722		

AB The invention relates to the application of N-acetyl-D-glucosamine to prepare the medical prepns. (such as injection, tablet, or capsule) for treating neoplasm and metastasis of neoplasm.

L14 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:142978 CAPLUS <<LOGINID::20070823>>
DN 140:175112
TI The use of N-acetyl-D-glucosamine for preparing medicines for urogenital tract infection treatment and prevention
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army P.R. of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014398	A1	20040219	WO 2003-CN664	20030813
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1475217	A	20040218	CN 2002-125486	20020813
	CA 2495684	A1	20040219	CA 2003-2495684	20030813
	AU 2003255111	A1	20040225	AU 2003-255111	20030813
	EP 1535620	A1	20050601	EP 2003-783908	20030813
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006142243	A1	20060629	US 2005-524476	20051011
PRAI	CN 2002-125486	A	20020813		
	WO 2003-CN664	W	20030813		

AB The use of N-acetyl-D-glucosamine for preparing medicines for the treatment and prevention in urogenital tract

infection is disclosed. N-acetyl-D-glucosamine can resist the homing of external microorganism and can further facilitate the rehabilitation of local skin tissue. The easily prepared formulation which mainly comprising N-acetyl-D-glucosamine can be used for urogenital tract infection treatment and prevention. The use of said formulation is effective and not-irritative, and does not lead to pollution.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675848 CAPLUS <<LOGINID::20070823>>
DN 137:195598
TI Application of N-acetyl-D-glucosamine in manufacturing drug for treating cardio-cerebrovascular ischemia
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067949	A1	20020906	WO 2002-CN123	20020228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1372934	A	20021009	CN 2001-104893	20010228
	AU 2002237183	A1	20020912	AU 2002-237183	20020228
	US 2004106577	A1	20040603	US 2004-469213	20040112
	US 7074774	B2	20060711		
PRAI	CN 2001-104893	A	20010228		
	WO 2002-CN123	W	20020228		

AB The present invention disclose the use of N-acetyl-D-glucosamine in the manufacture of drug for treating cardio-cerebrovascular ischemia and anoxia. N-acetyl-D-glucosamine is able to prolong the life time of exptl. animal under the condition of cerebrovascular ischemia and the environment of normal pressure and oxygen deficit, to reduce the degree of cerebral edema after reperfusion in cerebrovascular ischemia and the other symptom of neural behavior. The dosage form of this drug can be injection, tablet or capsule.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675847 CAPLUS <<LOGINID::20070823>>
DN 137:195621
TI Application of N-acetyl-D-glucosamine in manufacturing drug for preventing and treating sexual disorder
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army,

P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002067948	A1	20020906	WO 2002-CN122	20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1372930	A	20021009	CN 2001-104883	20010228
CN 1131037	B	20031217		
AU 2002235706	A1	20020912	AU 2002-235706	20020228
EP 1371371	A1	20031217	EP 2002-702210	20020228
EP 1371371	B1	20060614		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004522783	T	20040729	JP 2002-567315	20020228
US 2004092483	A1	20040513	US 2004-469325	20040105
US 7015207	B2	20060321		
PRAI CN 2001-104883	A	20010228		
WO 2002-CN122	W	20020228		

AB The present invention discloses the use of N-acetyl-D-glucosamine in manufacturing drug for preventing and treating sexual disorder. The formulation comprising of N-acetyl-D-glucosamine as main active ingredient is useful for preventing and treating sexual disorder with notable effect, convenient formulation and less side-effects. Its dosage form can be oral liqs., tincture or capsule.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675846 CAPLUS <<LOGINID::20070823>>
DN 137:195620
TI Application of N-acetyl-D-glucosamine in manufacturing drug for adjuvant treatment of perianal diseases
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002067947	A1	20020906	WO 2002-CN120	20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				

UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CN 1372932	A	20021009	CN 2001-104885	20010228
	CN 1131038	B	20031217		
	AU 2002235705	A1	20020912	AU 2002-235705	20020228
	US 2005119224	A1	20050602	US 2003-469284	20020228
PRAI	CN 2001-104885	A	20010228		
	WO 2002-CN120	W	20020228		

AB The present invention disclose the application of N-acetyl-D-glucosamine in manufacturing drug for adjuvant treatment of perianal diseases. By stabilizing membrane of cyto-lysosome, N-acetyl-D-glucosamine is able to suppress expansion of injury due to various enzyme releasing from cyto-lysosome, to promote healing of injured tissue; to inhibit localization and reproduction of organism at trauma and to control infection of organism. The formulation comprising of N-acetyl-D-glucosamine as main active ingredient is useful for adjuvant treatment of perianal diseases with significant effect.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675845 CAPLUS <<LOGINID::20070823>>
DN 137:195619
TI Application of N-acetyl-D-glucosamine in manufacturing drug for suppressing side-effects of radiotherapy and chemotherapy
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067946	A1	20020906	WO 2002-CN119	20020228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1372929	A	20021009	CN 2001-104882	20010228
	CN 1131036	B	20031217		
	AU 2002237181	A1	20020912	AU 2002-237181	20020228
	EP 1374873	A1	20040102	EP 2002-703474	20020228
	EP 1374873	B1	20050427		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AT 293983	T	20050515	AT 2002-703474	20020228
	US 2004077596	A1	20040422	US 2003-469327	20031217
	US 7037904	B2	20060502		
	HK 1061530	A1	20051118	HK 2004-104522	20040624
PRAI	CN 2001-104882	A	20010228		
	WO 2002-CN119	W	20020228		

AB The present invention discloses the application of N-acetyl-D-glucosamine in manufacturing drug for suppressing side-effects of radiotherapy and chemotherapy. The formulation comprising of N-acetyl D-glucosamine as main active ingredient is used in tumor patients for suppressing side-effects of radiotherapy and chemotherapy with total efficiency is up to 85%. Its dosage form can be oral liqs. or injection.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675844 CAPLUS <<LOGINID::20070823>>
DN 137:195618
TI Application of N-acetyl-D-glucosamine in manufacturing drug for treating uterus cervical erosion
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067945	A1	20020906	WO 2002-CN118	20020228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1372931	A	20021009	CN 2001-104884	20010228
	AU 2002235704	A1	20020912	AU 2002-235704	20020228
	US 2004138174	A1	20040715	US 2004-469268	20040302
	US 6992073	B2	20060131		
PRAI	CN 2001-104884	A	20010228		
	WO 2002-CN118	W	20020228		

AB The present invention disclose the application of N-acetyl-D-glucosamine in manufacturing drug for treating cervical erosion. N-acetyl-D-glucosamine is able to suppress the localization and reproduction of organism, to control infection of organism, to ameliorate local exudation, inflammatory edema of tissue and pain etc. Its dosage form can be liqs., emulsion, suppository, ointment, and cream.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675843 CAPLUS <<LOGINID::20070823>>
DN 137:195617
TI Application of N-acetyl-D-glucosamine in manufacturing drug for treating motion sickness
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2

```
DT   Patent
LA   Chinese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    --------------------     --------
PI   WO 2002067944        A1    20020906    WO 2002-CN117            20020228
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO,
            CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
            HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
            LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
            PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
            UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
            CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CN 1372933           A     20021009    CN 2001-104892           20010228
     AU 2002237180        A1    20020912    AU 2002-237180           20020228
     US 2004116383        A1    20040617    US 2004-469326           20040203
     US 6946452           B2    20050920
PRAI CN 2001-104892       A     20010228
     WO 2002-CN117        W     20020228
AB   The present invention discloses the application of N-
     acetyl-D-glucosamine in manufacturing drug for
     treating motion sickness.  The formulation comprising of N-
     acetyl-D-glucosamine as main active ingredient
     can be used in the prophylaxis and treatment of motion sickness with more
     than 90% efficiency.  Its dosage form can be oral liquid or tablet.
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s Yuan Zetao/AU
L15         19 YUAN ZETAO/AU

=> s l15 and N-acetyl-D-glucosamine
       3073272 N
        161766 ACETYL
            68 ACETYLS
        161802 ACETYL
                  (ACETYL OR ACETYLS)
       2482826 D
         22201 GLUCOSAMINE
           328 GLUCOSAMINES
         22304 GLUCOSAMINE
                  (GLUCOSAMINE OR GLUCOSAMINES)
          2882 N-ACETYL-D-GLUCOSAMINE
                  (N(W)ACETYL(W)D(W)GLUCOSAMINE)
L16          10 L15 AND N-ACETYL-D-GLUCOSAMINE

=> dis l16 1-10 bib abs

L16  ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:425901  CAPLUS <<LOGINID::20070823>>
DN   144:419764
TI   Antibacterial compositions of N-acetyl-d-aminoglycosamine and antibiotics
IN   Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA   Third Military Medical University, Chinese People's Liberation Army P.R.
     Of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New
     District Corporation, Ltd.
SO   PCT Int. Appl., 41 pp.
     CODEN: PIXXD2
DT   Patent
LA   Chinese
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005025582	A1	20050324	WO 2003-CN793	20030918
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003271022	A1	20050406	AU 2003-271022	20030918
	EP 1669077	A1	20060614	EP 2003-750251	20030918
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
	BR 2003018497	A	20060912	BR 2003-18497	20030918
	US 2007191291	A1	20070816	US 2007-572226	20070221
PRAI	CN 2003-108279	A	20030327		
	WO 2003-CN793	W	20030918		

AB The use of the combination of N-acetyl-D-glucosamine and antibiotics is disclosed, for the preparation of antibacterial drugs. In the therapies with antibacterial drugs, the pathogens may be changed into cryptic growth cells (CGCs), CGCs can colonize and thereby drug resistance arises. In the meantime, normal bacteria colonies in the body may be also changed into CGCs. These changes result in complications after the therapies, such as disorder of bacteria colonies in the body, disorder of GI functions and other chronic diseases. The combination of antibiotics and N-Acetyl-D-Aminoglycosamine can prevent of CGC, and the complications after antibiotics therapy. For example, i.m. injections contained N-acetyl-d-aminoglycosamine and kanamycin can prevent the GI tract bacteria changed into CGCs.

L16 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1007939 CAPLUS <<LOGINID::20070823>>
DN 142:148819
TI Application of N-acetyl-D-glucosamine to prepare medical preparation for regulating micro-ecological balance of skin mucosa
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA The Third Military Medical University of PLA, Peop. Rep. China; Bawei Medicine Development Institute Co., Ltd., Suzhou
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 8 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1470244	A	20040128	CN 2002-126833	20020722
PRAI	CN 2002-126833		20020722		

AB The invention relates to the application of N-acetyl-D-glucosamine to prepare medical prepns. (such as aqua preparation, emulsion, spray, cream, or ointment) for regulating micro-ecol. balance of skin mucosa.

L16 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1007938 CAPLUS <<LOGINID::20070823>>
DN 142:148766
TI Application of N-acetyl-D-glucosamine to prepare the medical preparation for treating neoplasm and metastasis of neoplasm
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao

PA The Third Military Medical University of PLA, Peop. Rep. China; Bawei Medicine Development Institute Co., Ltd., Suzhou
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 8 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1470243	A	20040128	CN 2002-126831	20020722
PRAI CN 2002-126831		20020722		

AB The invention relates to the application of N-acetyl-D-glucosamine to prepare the medical prepns. (such as injection, tablet, or capsule) for treating neoplasm and metastasis of neoplasm.

L16 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:142978 CAPLUS <<LOGINID::20070823>>
DN 140:175112
TI The use of N-acetyl-D-glucosamine for preparing medicines for urogenital tract infection treatment and prevention
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army P.R. of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014398	A1	20040219	WO 2003-CN664	20030813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1475217	A	20040218	CN 2002-125486	20020813
CA 2495684	A1	20040219	CA 2003-2495684	20030813
AU 2003255111	A1	20040225	AU 2003-255111	20030813
EP 1535620	A1	20050601	EP 2003-783908	20030813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006142243	A1	20060629	US 2005-524476	20051011
PRAI CN 2002-125486	A	20020813		
WO 2003-CN664	W	20030813		

AB The use of N-acetyl-D-glucosamine for preparing medicines for the treatment and prevention in urogenital tract infection is disclosed. N-acetyl-D-glucosamine can resist the homing of external microorganism and can further facilitate the rehabilitation of local skin tissue. The easily prepared formulation which mainly comprising N-acetyl-D-glucosamine can be used for urogenital tract infection treatment and prevention. The use of said formulation is effective and not-irritative, and does not lead to pollution.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675848 CAPLUS <<LOGINID::20070823>>
DN 137:195598
TI Application of N-acetyl-D-glucosamine in manufacturing drug for treating cardio-cerebrovascular ischemia
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067949	A1	20020906	WO 2002-CN123	20020228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1372934	A	20021009	CN 2001-104893	20010228
	AU 2002237183	A1	20020912	AU 2002-237183	20020228
	US 2004106577	A1	20040603	US 2004-469213	20040112
	US 7074774	B2	20060711		
PRAI	CN 2001-104893	A	20010228		
	WO 2002-CN123	W	20020228		

AB The present invention disclose the use of N-acetyl-D-glucosamine in the manufacture of drug for treating cardio-cerebrovascular ischemia and anoxia. N-acetyl-D-glucosamine is able to prolong the life time of exptl. animal under the condition of cerebrovascular ischemia and the environment of normal pressure and oxygen deficit, to reduce the degree of cerebral edema after reperfusion in cerebrovascular ischemia and the other symptom of neural behavior. The dosage form of this drug can be injection, tablet or capsule.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675847 CAPLUS <<LOGINID::20070823>>
DN 137:195621
TI Application of N-acetyl-D-glucosamine in manufacturing drug for preventing and treating sexual disorder
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2002067948 A1 20020906 WO 2002-CN122 20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CN 1372930 A 20021009 CN 2001-104883 20010228
CN 1131037 B 20031217
AU 2002235706 A1 20020912 AU 2002-235706 20020228
EP 1371371 A1 20031217 EP 2002-702210 20020228
EP 1371371 B1 20060614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004522783 T 20040729 JP 2002-567315 20020228
US 2004092483 A1 20040513 US 2004-469325 20040105
US 7015207 B2 20060321
PRAI CN 2001-104883 A 20010228
WO 2002-CN122 W 20020228

AB The present invention discloses the use of N-acetyl-D-glucosamine in manufacturing drug for preventing and treating sexual disorder. The formulation comprising of N-acetyl-D-glucosamine as main active ingredient is useful for preventing and treating sexual disorder with notable effect, convenient formulation and less side-effects. Its dosage form can be oral liqs., tincture or capsule.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675846 CAPLUS <<LOGINID::20070823>>
DN 137:195620
TI Application of N-acetyl-D-glucosamine in manufacturing drug for adjuvant treatment of perianal diseases
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002067947	A1	20020906	WO 2002-CN120	20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1372932	A	20021009	CN 2001-104885	20010228
CN 1131038	B	20031217		
AU 2002235705	A1	20020912	AU 2002-235705	20020228
US 2005119224	A1	20050602	US 2003-469284	20020228
PRAI CN 2001-104885	A	20010228		

WO 2002-CN120 W 20020228

AB The present invention disclose the application of N-acetyl-D-glucosamine in manufacturing drug for adjuvant treatment of perianal diseases. By stabilizing membrane of cyto-lysosome, N-acetyl-D-glucosamine is able to suppress expansion of injury due to various enzyme releasing from cyto-lysosome, to promote healing of injured tissue; to inhibit localization and reproduction of organism at trauma and to control infection of organism. The formulation comprising of N-acetyl-D-glucosamine as main active ingredient is useful for adjuvant treatment of perianal diseases with significant effect.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675845 CAPLUS <<LOGINID::20070823>>
DN 137:195619
TI Application of N-acetyl-D-glucosamine in manufacturing drug for suppressing side-effects of radiotherapy and chemotherapy
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067946	A1	20020906	WO 2002-CN119	20020228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1372929	A	20021009	CN 2001-104882	20010228
	CN 1131036	B	20031217		
	AU 2002237181	A1	20020912	AU 2002-237181	20020228
	EP 1374873	A1	20040102	EP 2002-703474	20020228
	EP 1374873	B1	20050427		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AT 293983	T	20050515	AT 2002-703474	20020228
	US 2004077596	A1	20040422	US 2003-469327	20031217
	US 7037904	B2	20060502		
	HK 1061530	A1	20051118	HK 2004-104522	20040624
PRAI	CN 2001-104882	A	20010228		
	WO 2002-CN119	W	20020228		

AB The present invention discloses the application of N-acetyl-D-glucosamine in manufacturing drug for suppressing side-effects of radiotherapy and chemotherapy. The formulation comprising of N-acetyl D-glucosamine as main active ingredient is used in tumor patients for suppressing side-effects of radiotherapy and chemotherapy with total efficiency is up to 85%. Its dosage form can be oral liqs. or injection.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675844 CAPLUS <<LOGINID::20070823>>
DN 137:195618
TI Application of N-acetyl-D-glucosamine in manufacturing drug for treating uterus cervical erosion
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067945	A1	20020906	WO 2002-CN118	20020228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1372931	A	20021009	CN 2001-104884	20010228
	AU 2002235704	A1	20020912	AU 2002-235704	20020228
	US 2004138174	A1	20040715	US 2004-469268	20040302
	US 6992073	B2	20060131		
PRAI	CN 2001-104884	A	20010228		
	WO 2002-CN118	W	20020228		

AB The present invention disclose the application of N-acetyl-D-glucosamine in manufacturing drug for treating cervical erosion. N-acetyl-D-glucosamine is able to suppress the localization and reproduction of organism, to control infection of organism, to ameliorate local exudation, inflammatory edema of tissue and pain etc. Its dosage form can be liqs., emulsion, suppository, ointment, and cream.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:675843 CAPLUS <<LOGINID::20070823>>
DN 137:195617
TI Application of N-acetyl-D-glucosamine in manufacturing drug for treating motion sickness
IN Xu, Qiwang; Liu, Junkang; Yuan, Zetao
PA Third Military Medical University, Chinese People's Liberation Army, P.R.of China, Peop. Rep. China; Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd.
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067944	A1	20020906	WO 2002-CN117	20020228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				

```
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CN 1372933           A     20021009    CN 2001-104892          20010228
     AU 2002237180        A1    20020912    AU 2002-237180          20020228
     US 2004116383        A1    20040617    US 2004-469326          20040203
     US 6946452           B2    20050920
PRAI CN 2001-104892       A     20010228
     WO 2002-CN117        W     20020228
AB   The present invention discloses the application of N-
     acetyl-D-glucosamine in manufacturing drug for
     treating motion sickness.  The formulation comprising of N-
     acetyl-D-glucosamine as main active ingredient
     can be used in the prophylaxis and treatment of motion sickness with more
     than 90% efficiency.  Its dosage form can be oral liquid or tablet.
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> dis hist

     (FILE 'HOME' ENTERED AT 15:08:37 ON 23 AUG 2007)

     FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT,
     NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2,
     WPIFV, WPINDEX, WSCA, WTEXTILES, BIOSIS, EMBASE, MEDLINE' ENTERED AT
     15:09:00 ON 23 AUG 2007
L1         48280 S N-ACETYLGLUCOSAMINE
L2          2862 S L1 AND (AUTOIMMU? OR LESION OR INFALM?)
L3          5069 S L1 AND (AUTOIMMU? OR LESION OR INFLAM?)
L4         12947 S L1 AND TREAT?
L5          3967 S L3 AND TREAT?
L6           243 S L1 AND (AUTOIMM?(S)REACTION)
L7           242 S L6 AND TREAT?
L8           208 S L7 AND DOSAGE
L9            47 S L8 AND (1000(A)MG)

     FILE 'CAPLUS' ENTERED AT 15:16:54 ON 23 AUG 2007
L10           33 S XU QIWANG/AU
L11            1 S L10 AND N-ACETYLGLUCOSAMINE
L12           14 S L10 AND N-ACETYL-D-GLUCOSAMINE
L13           45 S LIU JUNKANG/AU
L14           11 S L13 AND N-ACETYL-D-GLUCOSAMINE
L15           19 S YUAN ZETAO/AU
L16           10 S L15 AND N-ACETYL-D-GLUCOSAMINE
```